Treatment outcome for patients with primary nonsmall-cell lung cancer and synchronous brain metastasis.

The purpose of this study was to evaluate the outcome of treatment for pati ents with newly diagnosed nonsmall-cell lung cancer (NSCLC) with an isolate d, single, synchronous brain metastasis. A retrospective review was perform ed evaluating any patient diagnosed between 1982 and 1996 at the Cleveland Clinic Foundation with NSCLC metastatic only to the brain. Patients with mu ltiple brain metastases or with systemic metastases to any other organ were excluded. Survival was measured from the date of the first treatment for m alignancy. All hospital records were thoroughly reviewed in a retrospective manner. Thirty-three patients were identified who met the study criteria. Twelve patients had primary disease limited to the lung and hilar nodes, an d 21 had more advanced primary disease with involvement of the mediastinum. Treatment of the chest was considered aggressive in 13 patients and pallia tive in 15. The primary tumor was observed in 5 patients. The management of the brain metastasis was as follows: 21 patients underwent surgical resect ion and postoperative whole brain radiotherapy (WBRT), 5 underwent stereota ctic radiosurgery (SRS) and WBRT, 3 had resection alone, 2 had SRS alone, a nd 2 underwent WBRT alone. The median overall and disease-free survival for all patients was 6.9 months and 3.3 months, respectively. Overall survival was markedly improved with the addition of WEPT (P = 0.002) and with the a ggressive management of the primary tumor (P = 0.005). A total of 9 patient s experienced CNS failure, including both patients receiving WBRT alone. CN S failures were divided as follows: 3 local, 5 distant, and 1 local and dis tant. Two of the 4 patients with a local failure were salvaged, and ultimat e local control of the original brain metastasis was achieved in 93.6% of c ases. Survival remains poor for patients with Stage TV NSCLC even when meta static disease is limited to a single site within the brain; however, aggre ssive therapy of both the lung primary and the brain metastasis may provide a survival advantage. Excellent local control of single brain metastases w as achieved with a combination of WBRT with either surgical resection or SR S. (C) 1999 Wiley-Liss, Inc.